Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis

OBJECTIVES: Myeloablative autologous haematopoietic stem cell transplant (HSCT) was recently demonstrated to provide significant benefit over cyclophosphamide (CYC) in the treatment of diffuse cutaneous systemic sclerosis (dcSSc) in the Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial....

Descripción completa

Detalles Bibliográficos
Autores principales: Adamska, Julia Z, Zia, Amin, Bloom, Michelle S, Crofford, Leslie J, Furst, Daniel E, Goldmuntz, Ellen, Keyes-Elstein, Lynette, Mayes, Maureen D, McSweeney, Peter, Nash, Richard A, Pinckney, Ashley, Welch, Beverly, Love, Zelda Z, Sullivan, Keith M, Robinson, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Systemic Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918657/
https://www.ncbi.nlm.nih.gov/pubmed/36241361
http://dx.doi.org/10.1136/ard-2021-221925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918657/
https://www.ncbi.nlm.nih.gov/pubmed/36241361
http://dx.doi.org/10.1136/ard-2021-221925

Ejemplares similares